DISCLOSURE: This site receives compensation from featured companies, which may influence rankings. Read Advertising Disclosure
Orforglipron
pipelineInvestigational — PDUFA target action date April 2026; not yet FDA-approved
Est. Cost
$149-$399/mo (planned)
/month
Orforglipron is an investigational oral GLP-1 receptor agonist being developed by Eli Lilly. Unlike the Wegovy Pill, which is a peptide requiring specific fasting conditions for absorption, orforglipron is a small molecule that may be taken without food restrictions. If approved, it could represent a significant advancement in convenience for patients seeking oral GLP-1 therapy. The FDA's PDUFA target action date is April 2026, and the medication is not yet available for prescription.
Dosage Format
Daily oral tablet; no specific food restrictions anticipated based on trial data
Type
Pipeline
Best For
Patients interested in a future oral GLP-1 option without the food-timing restrictions of current oral semaglutide
Key Benefit
Orforglipron is Eli Lilly's investigational oral GLP-1 that, unlike the Wegovy Pill, is a small molecule rather than a peptide — meaning it may not require fasting or specific food-timing protocols and could be easier to manufacture at scale.
How Orforglipron Works
Orforglipron is a non-peptide small molecule that activates GLP-1 receptors in a similar manner to injectable semaglutide and tirzepatide. Because it is not a peptide, it does not require the specialized absorption enhancers or fasting protocols needed by oral semaglutide. Early clinical data suggests it may reduce appetite and promote weight loss through the same central nervous system pathways as other GLP-1 agonists. Its small molecule structure could also make it cheaper and easier to manufacture at scale compared to peptide-based alternatives.
Side Effects
Common
- • Nausea (reported in clinical trials)
- • Vomiting
- • Diarrhea
- • Constipation
- • Decreased appetite
Serious (Rare)
- • Clinical trial data is still being evaluated; full safety profile not yet established
- • GLP-1 class warnings (pancreatitis, gallbladder issues, thyroid tumors in animal models) may apply
- • Long-term safety data not yet available
Who Is Eligible
As an investigational medication, orforglipron is not yet available for prescription. If approved, eligibility criteria are expected to be similar to other GLP-1 weight loss medications: adults with a BMI of 30 or greater, or 27 or greater with weight-related conditions. Final prescribing information will be determined upon FDA approval.